Supplementary Figure S1 from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Figure S1. Changes from baseline in sum of target lesion diameters over time for patients continuing treatment after progression, either with adagrasib plus cetuximab (n = 38), adagrasib only (n = 10), or cetuximab only (n = 1). Only patients with available post-progression scans are included in the plot (n = 33 for adagrasib plus cetuximab; n = 1 for adagrasib only).
Authors: Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster, Tanios S. Bekaii-Saab, Minal Barve, Joel Saltzman, Joshua K. Sabari, Julio A. Peguero, Andrew Scott Paulson, Pasi A. Jänne, Marcia Cruz-Correa, Kenna Anderes, Karen Velastegui, Xiaohong Yan, Hirak Der-Torossian, Samuel J. Klempner, Scott E. Kopetz
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4399347641